I. K. Malashenkova

Learn More
We studied the state of antiviral defense in patients with severe course of herpetic infection of anogenital and labial localization and the frequency of its combination with other herpes virus infections. It was found that severe course of herpetic infection caused by herpes simplex virus occurs against the background of combined secondary immunodeficiency(More)
Coronary heart disease (CHD) was followed up in 239 patients with rheumatic heart disease. According to the clinical data 40 (16.73%) patients had myocardial infarction (MI), 100 (41.84%) cardiosclerosis (CS), 185 (77.4%) angina pectoris (AP). AP (44.35%) prevailed among the isolated (66.1%) forms of valvular disease, associated AP and CS (23%) among the(More)
OBJECTIVE to evaluate the levels of cytokines (IFNα, IFNγ, IL-2, Il-4, IL-6, IL-8, IL-10, IL-12, IL-15), IL-1β receptor antagonist (IL-1RA), vascular endothelial growth factor (VEGF) and its antagonist, the soluble form of receptor 1 (sVEGFR1) in the blood serum of patients with Alzheimer's disease, with early onset (ADEO) and late onset (ADLO), and in(More)
The authors present experimental data on luminol-dependent neutrophil chemiluminescence of blood from patients with drug intolerance. A decrease in intensity of neutrophil and whole blood chemiluminescence was registered in the presence of intolerated drugs. In acute phase of generalized intolerance reaction the chemiluminescence test showed readiness of(More)
AIM To study neutrophil bacterial and absorptive functions and the specific features of their impairments in gout. SUBJECTS AND METHODS The study included 48 male patients with a valid diagnosis of gout (mean age, 59.7 +/- 10.3 years; duration of the disease, 9.2 +/- 2.1 years; blood uric acid (UA), 520 +/- 80 micromol) (Group 1); 25 apparently healthy(More)
Objective. To assess the levels of cytokines (IFN-α, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-15, TNF-α) and IL-1 receptor antagonist (IL-1RA), as well as the levels of vascular endothelial growth factor (VEGF) and its antagonist – soluble receptor (sVEGFR1) – in the serum of patients with Alzheimer’s disease (AD) with early (EOAD) and late (LOAD) onset and(More)